Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.84 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
ContraFect Corp had its IPO on 2014-07-29 under the ticker symbol CFRX.
The company operates in the Healthcare sector and Biotechnology industry. ContraFect Corp has a staff strength of 38 employees.
Shares of ContraFect Corp opened at $2.29 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $2.12 - $2.43, and closed at $2.19.
This is a -4.37% slip from the previous day's closing price.
A total volume of 41,278 shares were traded at the close of the day’s session.
In the last one week, shares of ContraFect Corp have increased by +10.05%.
ContraFect Corp's Key Ratios
ContraFect Corp has a market cap of $2.84 million, indicating a price to book ratio of 0.4405 and a price to sales ratio of 0.
In the last 12-months ContraFect Corp’s revenue was $0 with a gross profit of $-1606434 and an EBITDA of $-64113000. The EBITDA ratio measures ContraFect Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ContraFect Corp’s operating margin was 0% while its return on assets stood at -79.64% with a return of equity of -239.32%.
In Q3, ContraFect Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
ContraFect Corp’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-126.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ContraFect Corp’s profitability.
ContraFect Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.163. Its price to sales ratio in the trailing 12-months stood at 0.
ContraFect Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $23.03 million
- Total Liabilities
- $23.78 million
- Operating Cash Flow
- $4.77 million
- Capital Expenditure
- Dividend Payout Ratio
ContraFect Corp ended 2023 with $23.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $23.03 million while shareholder equity stood at $-3103000.00.
ContraFect Corp ended 2023 with $0 in deferred long-term liabilities, $23.78 million in other current liabilities, 4000.00 in common stock, $-315865000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.66 million and cash and short-term investments were $17.65 million. The company’s total short-term debt was $667,000 while long-term debt stood at $0.
ContraFect Corp’s total current assets stands at $20.05 million while long-term investments were $0 and short-term investments were $12.98 million. Its net receivables were $586000.00 compared to accounts payable of $15.35 million and inventory worth $0.
In 2023, ContraFect Corp's operating cash flow was $4.77 million while its capital expenditure stood at $19000.
Comparatively, ContraFect Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
ContraFect Corp stock is currently trading at $2.19 per share. It touched a 52-week high of $363.2 and a 52-week low of $363.2. Analysts tracking the stock have a 12-month average target price of $3.67.
Its 50-day moving average was $4.02 and 200-day moving average was $36.03 The short ratio stood at 0.04 indicating a short percent outstanding of 0%.
Around 204.7% of the company’s stock are held by insiders while 1214.7% are held by institutions.
Frequently Asked Questions About ContraFect Corp
Similar Industry Stocks (Biotechnology)
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.